Cloverleaf Bio Raises $33M for tRNA Cancer Therapies

Cancer therapy development is full of elegant mechanisms that never survive the handoff from model to medicine. Cloverleaf Bio has raised a $33M Seed to test whether engineered transfer RNA can travel farther.

4BIO Capital led the upsized, oversubscribed financing. AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge participated.

The New Haven, Connecticut company plans to use the capital to advance an inhibitory tRNA program for hepatocellular carcinoma toward early clinical testing and an antibody-tRNA conjugate for colorectal cancer through preclinical development. The broader implication is a new attempt to turn RNA from biological machinery into a multi-target cancer payload, with the burden of human proof still ahead.

What Cloverleaf Bio Announced

Cloverleaf Bio announced the round on September 8, 2026. The company did not disclose its valuation, the financing instrument, ownership terms, individual check sizes, or a verified total-funding figure. The clean capital record is therefore a $33M Seed, not a larger number assembled from private-market estimates.

Austin Draycott, PhD, co-founder and CEO, Cole Lewis, PhD, co-founder and CSO, and Wendy Gilbert, PhD, co-founder and Scientific Advisory Board chair, built Cloverleaf Bio out of Yale RNA research. Gilbert remains a professor of molecular biophysics and biochemistry at Yale, where her work includes RNA regulation and modification.

The founders are pursuing a specific weakness in cancer biology. As tumor cells proliferate, they can become unusually dependent on enzymes that modify RNA. Cloverleaf's thesis is that an engineered tRNA can interfere with several of those enzymes at once, turning a familiar component of protein production into a selective therapeutic payload.

How the Engineered tRNA Platform Works

Transfer RNA normally helps a cell translate genetic instructions into proteins by carrying amino acids to the ribosome. Cloverleaf is engineering tRNAs with a 5-fluorouracil payload intended to trap multiple tRNA-modifying enzymes. The approach is designed to attack a group of dependencies rather than rely on one molecular target.

The lead compound, CLB-001, remains preclinical. Cloverleaf reports greater potency and selectivity for cancer cells than healthy tissue in preclinical studies, including activity in models resistant to frontline chemotherapy and current-generation antibody-drug-conjugate payloads. The company also reports no systemic-toxicity signal across the animal doses it tested.

Those statements describe laboratory and animal work, not human efficacy or safety. An NIH RePORTER record for National Cancer Institute project 1R44CA295426 independently confirms Cloverleaf Bio, CLB-001, the hepatocellular-carcinoma program, the engineered tRNA and 5-fluorouracil mechanism, and the preclinical work planned on the path toward an investigational-new-drug submission. It does not supply a clinical start date or human results.

Why This Investor Mix Matters

4BIO Capital focuses on advanced therapies for areas of high unmet need, which makes the firm a legible lead for a platform trying to create a new therapeutic modality. The participating syndicate adds 3 pharmaceutical venture arms. AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund are backing Cloverleaf before the company has disclosed human data.

Draper Associates and Mission BioCapital broaden the venture side of the round, while American Cancer Society BrightEdge brings an oncology impact-investment mandate. BrightEdge invests in early-stage cancer therapeutics, diagnostics, devices, and technologies, connecting a mission-driven source of capital to a company whose foundational research also received federal support.

That lineup is evidence of serious institutional interest in the mechanism and team. It is not a substitute for the development record Cloverleaf still has to build. Strategic investors may provide scientific and operating context, but a drug program advances through reproducible data, manufacturing control, regulatory work, and carefully designed human studies.

The Translation Work the Round Finances

Cloverleaf's first program targets hepatocellular carcinoma. The company says the financing will support proof-of-concept work and advancement toward early clinical testing. The timing of an IND filing, trial authorization, first patient, and clinical readout remains undisclosed.

The second program uses an antibody-tRNA conjugate for colorectal cancer. Cloverleaf has not disclosed the antibody target, clinical candidate, dose strategy, or development calendar. That program remains in preclinical development and should be judged on the evidence the company eventually releases.

The two-program design gives Cloverleaf a way to test both the core inhibitory tRNA concept and a more targeted delivery format. It also creates 2 different development burdens. Each program will need its own evidence for distribution, potency, selectivity, tolerability, manufacturing, and durability before the platform can claim broader reach.

This is the same transition that defines other early therapeutic financings. DevCuration's coverage of Typewriter Therapeutics' $56M in vivo CAR T round and Superluminal Medicines' $60M Series B shows how capital begins to change meaning when a company moves from platform possibility toward clinical obligations.

What the $33M Changes

The round gives Cloverleaf Bio a larger budget for the unglamorous work between a compelling preclinical result and a credible clinical-development package. That includes making the drug reproducibly, understanding how it moves through the body, defining toxicology margins, preparing regulatory evidence, and designing a study that can answer a narrow human question.

It also moves the company into a more visible form of accountability. Cloverleaf has described a multi-enzyme mechanism, 2 cancer programs, and a preclinical profile that attracted specialist, strategic, generalist, and impact investors. The next useful evidence will come from the development chain itself: candidate selection, manufacturing readiness, regulatory progress, and eventually data from people.

Transfer RNA is one of biology's oldest couriers. Cloverleaf Bio has $33M to find out whether an engineered version can carry a cancer program through every scientific and operational handoff required to become a medicine.